MedTrace Logo

A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects

NCT00666705 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2013-01-25

Study results available
· View outcomes & findings →

Summary

An open label study to evaluate an interaction between maraviroc and raltegravir in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

Maraviroc

300 milligrams(mg) every 12 hours Days 6-11

DRUG

Maraviroc

Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)

DRUG

Raltegravir

Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)

DRUG

Raltegravir

400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00666705 on ClinicalTrials.gov